Rob Dillard

DocwireNews

Older breast cancer survivors, particularly those who underwent chemotherapy, biologically age at a faster rate than noncancer patients and may have worse outcomes, according to a <a href="https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34818">study</a> published in the journal Cancer.Cancer is predominately a disease of older age, and 60% of women newly diagnosed with breast cancer are 60 years or older. Treating and caring for older women with breast cancer can be challenging because even at the same chronological age, women may vary significantly in biological age. &ldquo;Biological aging refers to a gradual and progressive process of damage accumulation within systems that results from life course experiences and exposures and leads to a loss of system reserve and increased risk of cancer and other age-related diseases, disability, and mortality,&rdquo; the researchers wrote.Previous studies have shown that breast cancer survivors have short-term increases in biological age up to 1 year following treatment based on assessing epigenic measures, which capture biological aging over the life course. Less is known about long-term effects on older women or measured biological aging in noncancer individuals.To conduct their analysis, Kelly E. Rentscher, PhD, and colleagues analyzed 89 nonmetastatic breast cancer survivors and 101 controls. Patients in the population of interest were between 62 and 84 years old and provided 2 blood samples to derive epigenic age, which was measured using the Horvath, Extrinsic Epigenic Age (EEA), Phenotypic Age, and GrimAge epigenic clocks, as well as the Dunedin Pace of Aging (DunedinPACE) methylation measure. The subjects also completed cognitive and physical function assessments at approximately 24 to 36 and 60 months after study enrollment.Survivors Display Greater Biological AgingAccording to the findings, breast cancer survivors were 1.04 to 2.22&nbsp;years biologically older than the controls based on Horvath, EEA, GrimAge, and DunedinPACE measures (P=.001-.040) at approximately 24 to 36&nbsp;months after enrollment. The investigators observed that survivors exposed to chemotherapy were 1.97 to 2.71&nbsp;years older (P=.001-.040), and in this group, an older EEA was associated with worse self-reported cognition (P=.047) relative to the controls. Moreover, an older epigenetic age was correlated with worse physical function in all women (P&lt;.001-.010). The researchers noted that while survivors and controls showed similar epigenetic aging over time, Black survivors showed accelerated aging relative to non-Hispanic White survivors.&ldquo;This is the first investigation of longer-term biological aging in older breast cancer survivors and matched noncancer controls. We found that survivors showed greater biological aging, as measured by epigenetic assays, than controls. Older breast cancer survivors who had received chemotherapy showed the greatest epigenetic aging, and among this group, an older epigenetic age was associated with worse self-reported cognition,&rdquo; the researchers concluded. They added that, &ldquo;if replicated, measurement of biological aging could complement geriatric assessments to guide cancer care for older women.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Older Breast Cancer Survivors Biologically Age at a Faster Rate, Have Worse Health Outcomes

Breast Cancer News

Older breast cancer survivors biologically age at a faster rate than noncancer patients and may have worse outcomes.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe